Chapter/Section Purchase

1 Study Coverage
1.1 Poxviridae Infections Drug Product Introduction
1.2 Global Poxviridae Infections Drug Outlook 2017 VS 2022 VS 2028
1.2.1 Global Poxviridae Infections Drug Sales in US$ Million for the Year 2017-2028
1.2.2 Global Poxviridae Infections Drug Sales in Volume for the Year 2017-2028
1.3 United States Poxviridae Infections Drug Outlook 2017 VS 2022 VS 2028
1.3.1 United States Poxviridae Infections Drug Sales in US$ Million for the Year 2017-2028
1.3.2 United States Poxviridae Infections Drug Sales in Volume for the Year 2017-2028
1.4 Poxviridae Infections Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Poxviridae Infections Drug in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Poxviridae Infections Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Poxviridae Infections Drug Market Dynamics
1.5.1 Poxviridae Infections Drug Industry Trends
1.5.2 Poxviridae Infections Drug Market Drivers
1.5.3 Poxviridae Infections Drug Market Challenges
1.5.4 Poxviridae Infections Drug Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Poxviridae Infections Drug Market Segment by Type
2.1.1 CJ-40011
2.1.2 24a
2.1.3 BA-368
2.1.4 Others
2.2 Global Poxviridae Infections Drug Market Size by Type
2.2.1 Global Poxviridae Infections Drug Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Poxviridae Infections Drug Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Poxviridae Infections Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Poxviridae Infections Drug Market Size by Type
2.3.1 United States Poxviridae Infections Drug Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Poxviridae Infections Drug Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Poxviridae Infections Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Poxviridae Infections Drug Market Segment by Application
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Poxviridae Infections Drug Market Size by Application
3.2.1 Global Poxviridae Infections Drug Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Poxviridae Infections Drug Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Poxviridae Infections Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Poxviridae Infections Drug Market Size by Application
3.3.1 United States Poxviridae Infections Drug Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Poxviridae Infections Drug Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Poxviridae Infections Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Poxviridae Infections Drug Competitor Landscape by Company
4.1 Global Poxviridae Infections Drug Market Size by Company
4.1.1 Top Global Poxviridae Infections Drug Manufacturers Ranked by Revenue (2021)
4.1.2 Global Poxviridae Infections Drug Revenue by Manufacturer (2017-2022)
4.1.3 Global Poxviridae Infections Drug Sales by Manufacturer (2017-2022)
4.1.4 Global Poxviridae Infections Drug Price by Manufacturer (2017-2022)
4.2 Global Poxviridae Infections Drug Concentration Ratio (CR)
4.2.1 Poxviridae Infections Drug Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Poxviridae Infections Drug in 2021
4.2.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Poxviridae Infections Drug Manufacturing Base Distribution, Product Type
4.3.1 Global Poxviridae Infections Drug Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Poxviridae Infections Drug Product Type
4.3.3 Date of International Manufacturers Enter into Poxviridae Infections Drug Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Poxviridae Infections Drug Market Size by Company
4.5.1 Top Poxviridae Infections Drug Players in United States, Ranked by Revenue (2021)
4.5.2 United States Poxviridae Infections Drug Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Poxviridae Infections Drug Sales by Players (2020, 2021 & 2022)
5 Global Poxviridae Infections Drug Market Size by Region
5.1 Global Poxviridae Infections Drug Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Poxviridae Infections Drug Market Size in Volume by Region (2017-2028)
5.2.1 Global Poxviridae Infections Drug Sales in Volume by Region: 2017-2022
5.2.2 Global Poxviridae Infections Drug Sales in Volume Forecast by Region (2023-2028)
5.3 Global Poxviridae Infections Drug Market Size in Value by Region (2017-2028)
5.3.1 Global Poxviridae Infections Drug Sales in Value by Region: 2017-2022
5.3.2 Global Poxviridae Infections Drug Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Poxviridae Infections Drug Market Size YoY Growth 2017-2028
6.1.2 North America Poxviridae Infections Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Poxviridae Infections Drug Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Poxviridae Infections Drug Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Poxviridae Infections Drug Market Size YoY Growth 2017-2028
6.3.2 Europe Poxviridae Infections Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Poxviridae Infections Drug Market Size YoY Growth 2017-2028
6.4.2 Latin America Poxviridae Infections Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Poxviridae Infections Drug Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Poxviridae Infections Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Bavarian Nordic A/S
7.1.1 Bavarian Nordic A/S Corporation Information
7.1.2 Bavarian Nordic A/S Description and Business Overview
7.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Products Offered
7.1.5 Bavarian Nordic A/S Recent Development
7.2 BioFactura, Inc.
7.2.1 BioFactura, Inc. Corporation Information
7.2.2 BioFactura, Inc. Description and Business Overview
7.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.2.4 BioFactura, Inc. Poxviridae Infections Drug Products Offered
7.2.5 BioFactura, Inc. Recent Development
7.3 CEL-SCI Corporation
7.3.1 CEL-SCI Corporation Corporation Information
7.3.2 CEL-SCI Corporation Description and Business Overview
7.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.3.4 CEL-SCI Corporation Poxviridae Infections Drug Products Offered
7.3.5 CEL-SCI Corporation Recent Development
7.4 Chimerix, Inc.
7.4.1 Chimerix, Inc. Corporation Information
7.4.2 Chimerix, Inc. Description and Business Overview
7.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Chimerix, Inc. Poxviridae Infections Drug Products Offered
7.4.5 Chimerix, Inc. Recent Development
7.5 China Biologic Products, Inc.
7.5.1 China Biologic Products, Inc. Corporation Information
7.5.2 China Biologic Products, Inc. Description and Business Overview
7.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Products Offered
7.5.5 China Biologic Products, Inc. Recent Development
7.6 CJ HealthCare Corp.
7.6.1 CJ HealthCare Corp. Corporation Information
7.6.2 CJ HealthCare Corp. Description and Business Overview
7.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Products Offered
7.6.5 CJ HealthCare Corp. Recent Development
7.7 EpiVax, Inc.
7.7.1 EpiVax, Inc. Corporation Information
7.7.2 EpiVax, Inc. Description and Business Overview
7.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.7.4 EpiVax, Inc. Poxviridae Infections Drug Products Offered
7.7.5 EpiVax, Inc. Recent Development
7.8 N & N Pharmaceuticals Inc.
7.8.1 N & N Pharmaceuticals Inc. Corporation Information
7.8.2 N & N Pharmaceuticals Inc. Description and Business Overview
7.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Products Offered
7.8.5 N & N Pharmaceuticals Inc. Recent Development
7.9 SIGA Technologies, Inc.
7.9.1 SIGA Technologies, Inc. Corporation Information
7.9.2 SIGA Technologies, Inc. Description and Business Overview
7.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Products Offered
7.9.5 SIGA Technologies, Inc. Recent Development
7.10 Takeda Pharmaceutical Company Limited
7.10.1 Takeda Pharmaceutical Company Limited Corporation Information
7.10.2 Takeda Pharmaceutical Company Limited Description and Business Overview
7.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Products Offered
7.10.5 Takeda Pharmaceutical Company Limited Recent Development
7.11 Tonix Pharmaceuticals Holding Corp.
7.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
7.11.2 Tonix Pharmaceuticals Holding Corp. Description and Business Overview
7.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Products Offered
7.11.5 Tonix Pharmaceuticals Holding Corp. Recent Development
7.12 Verrica Pharmaceuticals Inc.
7.12.1 Verrica Pharmaceuticals Inc. Corporation Information
7.12.2 Verrica Pharmaceuticals Inc. Description and Business Overview
7.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Verrica Pharmaceuticals Inc. Products Offered
7.12.5 Verrica Pharmaceuticals Inc. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Poxviridae Infections Drug Industry Chain Analysis
8.2 Poxviridae Infections Drug Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Poxviridae Infections Drug Distributors
8.3 Poxviridae Infections Drug Production Mode & Process
8.4 Poxviridae Infections Drug Sales and Marketing
8.4.1 Poxviridae Infections Drug Sales Channels
8.4.2 Poxviridae Infections Drug Distributors
8.5 Poxviridae Infections Drug Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer